Point of Care Decision Support Announces Partnership with CoaguSense, Inc.

Anticoagulation Clinical Decision Support Software and Prothrombin Time (PT/INR) Monitoring System Focuses on Personalized Medicine and Managing Therapy through Technology-Enabled Engagement.

 

St. Paul, MN. (April 10, 2019) Point of Care Decision Support (PCDS), developer of an integrated electronic clinical decision support software for comprehensive individual patient care management and complex medication paradigms for patients with severe, chronic conditions; and CoaguSense, Inc., manufacturer of the world’s most precise portable PT/INR monitoring system using direct mechanical clot detection for patients on an anticoagulant therapy announce their strategic partnership. 

 

This agreement brings together the leading evidence-based anticoagulation software that improves clinical outcomes and optimizes patient care and the recently FDA cleared Coag-Sense® PT2 PT/INR Monitoring System - a new compact PT/INR meter that allows clinicians and patients to connect to the PCDS patient management solution.  Together they help streamline the care workflow while allowing the clinician and patient to make informed decisions together about their anticoagulant therapy.

 

PCDS President and CEO, Jaime Ojeda says, “CoaguSense is a great partner for PCDS because its Coag-Sense meter is simple to use and offers a wide variety of connectivity solutions including Wi-Fi and Bluetooth. Our clients continue to strive for more comprehensive home monitoring solutions to better care for their patients; the PCDS and CoaguSense partnership enables patients and their care providers to drive better outcomes in the new era of digital health.”   

 

CoaguSense CEO, Doug Patterson contributes, “PCDS fills a significant unmet need by offering a comprehensive patient anticoagulation management solution that can easily and affordably be implemented by all care providers, even smaller physician practices.”

 

Point of Care Decision Support and CoaguSense will be demonstrating their products at the upcoming AC Forum Conference for physicians, nurses and pharmacists that work with patients on oral anticoagulant therapies in Fort Lauderdale, Florida, April 11-13.  Point of Care will hold a Symposium titled, “How Evidence-Derived Clinical Decision Support within Electronic Health Records Can Improve Delivery of Optimized Anticoagulant Therapy: The Point of Care AC Decision Support Experience” and welcome any conference attendees to register.

 

                                                                                     ###                                                      

About Point of Care Decision Support

Point of Care Decision Support, LLC (PCDS) is a healthcare software company driving healthcare quality across the continuum of care.  With its Dynamic Decision Support Platform as a core anchor, PCDS builds intuitive healthcare tools that measure and improve the quality of patient care, provide real-time data and analysis, and have a meaningful and measurable return on investment.  Interoperable with all major EMR systems, the applications easily integrate new technology with existing investments, reducing implementation and operating costs.  PCDS believes that the complexity of patient care can be captured in a clear and meaningful way, enabling informed decision-making throughout the coordination and management of care. Visit www.ptofcare.com to learn more about their anticoagulation (AC), asthma and other chronic disease applications in their solutions portfolio.

 

About CoaguSense, Inc.

Based in Fremont, California, CoaguSense was founded in 2008 to bring more accurate and robust anticoagulation monitoring technology to both clinicians and patients. The company’s lead product is the Coag-Sense PT/INR Monitoring System, which incorporates a novel direct micromechanical clot-detection technology. This proprietary technology emulates the World Health Organization (WHO) gold standard tilt-tube method while requiring only a very small blood sample. Direct clot-detection technology provides clinicians with the system reliability they demand and patients with the comfort of knowing that proper home testing can provide dependable results like a laboratory. In 2016, CoaguSense was acquired by i-SENS, Inc.—a leader in point-of-care diagnostic technology and manufacturing. Further information about CoaguSense can be found at www.coag-sense.com

 

Coag-Sense is a registered trademark of CoaguSense. All other trademarks are the property of their respective owners.